



Press Contact

Alexander Herrmann
CFO
Capsulation NanoScience AG
+49 (0) 30 670 6919-0
E-mail: alexander.herrmann@capsulation.com

Dr. Ernst Böhnlein
CEO
NascaCell Technologies AG
+49 (0) 89 /547272 - 0
E-mail: e.boehnlein@nascacell.de

NASCACELL and CAPSULATION start joint development program

The Novel development for target validation, drug discovery and therapy

Munich / Berlin, 14th August, 2007 --- Munich-based NascaCell Technologies AG and Capsulation Nanoscience AG, Berlin, signed a joint development and license option agreement. As part of this joint development program, NascaCell as leading provider of customized aptamers and Microbodies™ and Capsulation, an internationally renowned developer of nano-complexes and –capsules, will develop innovative solutions for improved delivery of aptamers and other nucleic acids into cells. The joint development will benefit from the combination of advanced nano-technologies and efficient transport peptides and will generate innovative, target-specific delivery systems for biomolecules into cells and experimental animals.

Specifically, the partners will couple aptamers to functional peptide nanoparticles with subsequent analyses in cellular assays as well as animal studies. The nano-particles and -capsules are also suitable to deliver drug development candidates and will be optimized in this direction.

„We expect additional growth of our aptamer service business, in particular for intracellular applications, from this combination of our gene transfer know how and Capsulation`s established formulation expertise. Furthermore, these new methods will also be applicable for other applications such as therapeutic RNAi. Capsulation with an established track record of its innovative technology is an ideal partner in this endeavour, “ says Dr. Ernst Boehnlein, CEO of NascaCell.

In addition to the application of its technologies by its partner, Capsulation expects gain of additional know how. “NascaCell has a unique experience in the areas of target validation and drug discovery from which we can benefit in the development of custom-tailored solutions,” says Alexander Herrmann, CFO of Capsulation.

About Capsulation:

Capsulation NanoScience AG is a leading nanotechnology company focusing on the development of tailor-made drug delivery systems and other innovative life science products based on tunable nano-sized capsules. The company applies its worldwide-patented so-called LBL-Technology[®]. Based on their minute size, their functionality and their highly reproducible production process the tunable capsules can be used for a multitude of different applications. Accordingly, the precisely sized capsules can be made to function in a manner to suit the intended application, and can be given the appropriate biochemical, electrical, optical and magnetic properties as required by the customer.

About NascaCell Technologies AG:

NascaCell Technologies AG, based in Munich, is a global leading provider of a new generation of biomolecules. With the innovative Aptamer and MicrobodyTM technologies, the company supports customers in the target validation and drug discovery R&D areas. NascaCell also develops a line of products and drug development candidates based on the MicrobodyTM technology.